{"Increase in insulin prices": "The expert's verdict states that insulin prices have \"gone THRU THE ROOF for patients/taxpayers\" due to the practices of manufacturers, health plans, and pharmacy benefit managers (PBMs). This aspect highlights the claim that insulin prices have significantly increased.", "Impact on affordability": "The expert mentions that some people struggle to afford the cost of insulin, indicating that the high prices have a direct impact on the affordability of the drug for patients and taxpayers.", "Ballooning list prices": "The expert refers to the fact that manufacturers, health plans, and PBMs make money as a percentage of the ballooning list price of insulin. This suggests that the list prices of insulin have been rising, contributing to the higher costs for patients and taxpayers.", "Testimony from industry representatives": "The expert mentions a House Committee hearing that featured testimony from CVS Health, Express Scripts, OptumRx, Eli Lilly and Company, Novo Nordisk, and Sanofi. These representatives claimed that they couldn't lower the prices of insulin due to the operations of PBMs and health insurance companies. This aspect highlights the involvement of various stakeholders in the pricing and accessibility of insulin."}